A5040405517- Advanced Breast Cancer Therapies
- Hair Growth and Disorders
- Breast Cancer Treatment Studies
- Health Systems, Economic Evaluations, Quality of Life
- Cancer Treatment and Pharmacology
- Multiple and Secondary Primary Cancers
- Wound Healing and Treatments
- Dermatology and Skin Diseases
- Economic and Financial Impacts of Cancer
- Diabetes Management and Research
- Diabetes Treatment and Management
- Dermatologic Treatments and Research
- Cancer-related cognitive impairment studies
- Dupuytren's Contracture and Treatments
- Global Cancer Incidence and Screening
- RNA regulation and disease
- Cancer Risks and Factors
- Healthcare cost, quality, practices
- Cancer survivorship and care
- Autoimmune and Inflammatory Disorders
- Atrial Fibrillation Management and Outcomes
- Lung Cancer Research Studies
- Diabetes and associated disorders
- Pharmaceutical Practices and Patient Outcomes
- BRCA gene mutations in cancer
Pfizer (United States)
2019-2025
University Hospitals of Morecambe Bay NHS Foundation Trust
2024
Impact Technology Development (United States)
2019-2022
University of Illinois Chicago
2014-2022
Case Western Reserve University
2019
McMaster University
2018
Impact
2018
Children's Hospital of Pittsburgh
2018
Washington University in St. Louis
2018
University of Colorado Denver
2017
ObjectiveTo derive a US-based value set for the EQ-5D-5L questionnaire using an international, standardized protocol developed by EuroQol Group.MethodsRespondents from US adult population were quota-sampled on basis of age, sex, ethnicity, and race. Trained interviewers guided participants in completing composite time trade-off (cTTO) discrete choice experiment (DCE) tasks Valuation Technology software routine quality control measures. Data modeled Tobit model cTTO data, mixed logit DCE...
ObjectivesThe wording of the Hungarian EQ-5D-3L and EQ-5D-5L descriptive systems differ a great deal. This study aimed to (1) develop value sets for Hungary from common sample, (2) compare how level affected valuations.MethodsIn 2018 2019, 1000 respondents, representative general population, completed composite time trade-off tasks. Pooled heteroscedastic Tobit models were used estimate sets. Value set characteristics, single-level transition utilities adjacent corner health states, mean all...
This subgroup analysis of the ALLEGRO phase 2b/3 trial (NCT03732807) evaluated efficacy and safety ritlecitinib, an oral, selective dual JAK3/TEC family kinase inhibitor, for treatment alopecia areata (AA) in patients aged 12-17 years.In ALLEGRO-2b/3, ≥12 years with AA ≥50% scalp hair loss received once-daily ritlecitinib 50 or 30 mg (±4-week 200-mg loading dose) 10 placebo 24 weeks. In a subsequent 24-week extension period, groups continued their doses, initially assigned to switched 200/50...
Ritlecitinib is an oral Janus kinase 3/tyrosine expressed in hepatocellular carcinoma (JAK3/TEC) family inhibitor approved for the treatment of severe alopecia areata (AA). Benefit-risk profiles two doses ritlecitinib (50 mg vs 30 once daily) were evaluated by integrating patient preferences and clinical efficacy safety estimates ritlecitinib. A discrete-choice experiment (DCE) was utilized to elicit benefit attributes systemic AA treatments. Benefits included probabilities ≥80% scalp hair...
Abstract Background ALLEGRO‐LT is an ongoing, long‐term, open‐label, multicentre, phase 3 study of ritlecitinib in adults and adolescents with alopecia areata (AA). Objectives To evaluate safety efficacy through Month 24 patients AA ≥25% scalp hair loss. Methods enrolled rollover who previously received intervention either ALLEGRO 2a or 2b/3 studies de novo had not treatment study. The cohort results are reported here. Patients aged ≥12 years loss a daily, 4‐week 200‐mg loading dose,...
ABSTRACT Background Hair loss due to alopecia areata (AA) can negatively impact patients’ health‐related quality of life (HRQoL). Patient‐reported outcome measures (PROMs) like the EQ‐5D‐5L and Alopecia Areata Patient Priority Outcomes (AAPPO) represent treatment outcomes guide decision‐making. However, potentially underestimates AA‐specific impacts, while AAPPO may provide a more disease‐specific assessment. Objectives This study uses emotional symptom (ES) activity limitations (AL)...
Purpose: Alopecia areata (AA), an autoimmune disorder characterized by non-scarring hair loss, is detrimental to the psychological health and quality of life people living with AA. Clinically meaningful regrowth possible, but relationship downstream patient-reported outcomes (PROs) complex.
None.
OBJECTIVE Obese youth without diabetes with monophasic oral glucose tolerance test (OGTT) response curves have lower insulin sensitivity and impaired β-cell function compared those biphasic curves. The OGTT curve has not been studied in youth-onset type 2 diabetes. Here we the hypothesis that at randomization TODAY (Treatment Options for Type Diabetes Adolescents Youth) study forecasts heightened glycemic failure rates accelerated decline function. RESEARCH DESIGN AND METHODS OGTTs (n = 662)...
Diabetic nephropathy (DN) is a progressive kidney disease resulting as complication of diabetes mellitus. This study evaluated the progression and economic burden DN among commercially insured patients with type 2 in USA. The research design was retrospective observational based on healthcare claims data. Truven MarketScan Databases (2004–2014) were queried for adults at least one urine albumin test (index, randomly selected) after diagnosis index. On basis index test, classified into...
Objective. To compare and contrast EQ-5D-5L (5L) EQ-5D-3L (3L) health state values derived from a common sample. Methods. Data the 2017 US EQ-5D valuation study were analyzed. Value sets estimated with random-effects linear regression based on composite time trade-off (cTTO) valuations for 3L 5L states 2 approaches to model specification: main effects only additional N3/N45 terms. Properties of descriptive system value set characteristics compared by examining distributions predicted index...
Abstract Purpose Alopecia areata (AA) is an autoimmune-mediated inflammatory dermatological disease characterised by non-scarring hair loss affecting the scalp and sometimes other hair-bearing sites. This study aimed to elicit health state utility values (HSUVs) from UK general population for AA using time trade off (TTO) interviews. Methods Vignette descriptions of states defined extent were developed (as well as one describing caregiver burden). These data standardised patient reported...
Ritlecitinib demonstrated efficacy in patients with alopecia areata (AA) the ALLEGRO phase 2b/3 study (NCT03732807). However, hair loss presentation may vary based on location (e.g., scalp, eyebrow/eyelash, body). Here, we sought to identify distinct profiles at baseline and evaluate whether they affected of ritlecitinib.Patients AA aged ≥ 12 years 50% scalp were randomized daily ritlecitinib 10 mg (assessed for dose ranging only), 30 or 50 (± 4-week, 200-mg loading dose), placebo 24 weeks....